WU Sifan, TAN Changyu, FAN Hongbin, YIN Xiaoxing, LU Qian. A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 373-378. doi: 10.3969/j.issn.1006-0111.2018.04.020
| Citation:
|
WU Sifan, TAN Changyu, FAN Hongbin, YIN Xiaoxing, LU Qian. A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 373-378. doi: 10.3969/j.issn.1006-0111.2018.04.020
|
A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy
- 1.
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China
- 2.
Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China
- Received Date: 2017-10-19
- Rev Recd Date:
2018-03-26
-
Abstract
Objective To evaluate the efficacy and safety of oxcarbazepine and carbamazepine in treating post-stroke epilepsy. Methods PubMed, Cochrane Library, EMbase, VIP, CNKI and CBM were used for searching literatures related to oxcarbazepine and carbamazepine in the treatment of post-stroke epilepsy before August 2017, followed with RevMan5.3 software for data analysis. Results 6 studies were included with 517 patients. Meta-analysis showed that the total effective rate in oxcarbazepine group was higher than carbamazepine group with statistical significance (RR=1.44,95%CI:1.29~1.60,P<0.000 01). The incidence of total adverse reactions in oxcarbazepine group was also statistically significant lower than carbamazepine group (RR=0.39,95%CI:0.26~0.57,P<0.000 01). There was no statistically significant difference (P>0.05) in rash, dizziness, somnolence, nausea and vomiting between two groups. Conclusion Our analysis indicated that oxcarbazepine had better efficacy than carbamazepine in treating post-stroke epilepsy with less adverse reactions. Due to the limited number of literatures and sample size, large samples with multi-center and high quality clinical randomized controlled trials are needed to confirm the credibility of our conclusions.
-
References
|
[1]
|
ZELANO J. Poststroke epilepsy:update and future directions[J]. Ther Adv Neurol Disord,2016,9(5):424-435. |
|
[2]
|
ZELANO J,LUNDBERG RG,BAARS L,et al. Clinical course of poststroke epilepsy:a retrospective nested case-control study[J]. Brain Behav,2015,5(9):e00366. |
|
[3]
|
中华医学会神经病学分会脑电图与癫痫学组. 抗癫痫药物应用专家共识[J].中华神经科杂志,2011,44(1):20-21. |
|
[4]
|
杨丹. 奥卡西平和卡马西平治疗脑卒中后继发性癫痫的疗效对比和康复分析[J]. 中国伤残医学,2017,25(1):49-50. |
|
[5]
|
侯蕴祈. 奥卡西平与卡马西平单药治疗脑梗死后迟发型癫痫的对照研究[J]. 中国当代医药,2010,17(15):52-53. |
|
[6]
|
丁年东. 奥卡西平与卡马西平治疗脑卒中后继发性癫痫的疗效对比观察[J]. 临床合理用药杂志,2016,9(24):42-43. |
|
[7]
|
马刚. 奥卡西平与卡马西平治疗脑卒中后继发性癫痫对比研究[J]. 中国实用神经疾病杂志,2015,18(14):24-25. |
|
[8]
|
王艳,赵新利,吴新艳,等. 奥卡西平与卡马西平治疗脑卒中后继发性癫痫疗效比较[J].新乡医学院学报,2014,31(4):312-314. |
|
[9]
|
韦韬,邱小鹰,陈红,等. 奥卡西平与卡马西平在脑卒中后继发性癫痫的疗效观察[J]. 医学信息,2016,29(9):267-267. |
|
[10]
|
SZOEKE CE,NEWTON M,WOOD JM,et al. Update on pharmacogenetics in epilepsy:a brief review[J]. Lancet Neurol,2006,5(2):189-196. |
|
[11]
|
BOOTSMA HP,RICKER L,DIEPMAN L,et al. Levetiracetam in clinical practice:long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center[J]. Epilepsy Behav,2007,10(2):296-303. |
|
[12]
|
ROUAN MC,LECAILLON JB,GODBILLON J,et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites[J]. Eur J Clin Pharmacol,1994,47(2):161-167. |
|
[13]
|
ANTUNES NJ,VAN DIJKMAN SC,LANCHOTE VL,et al. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects[J]. Eur J Pharm Sci,2017,109S:S116-S123. |
|
[14]
|
RYVLIN P,MONTAVONT A,NIGHOGHOSSIAN N. Optimizing therapy of seizures in stroke patients[J]. Neurology,2006,67(4):3-9. |
-
-
Proportional views
-
DownLoad: